Search Results

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session

U.S. Army Institute of Surgical Research to conduct key studies intended to further our knowledge of the effects of Claromer technology

Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials.

- Company listed in Research and Markets’ announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - “U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"- -Report supports Company’s regulatory strategy for IzoView Breast CT, reinforces high demand for new breast imaging modalities, strengthens the potential for rapid market adoption and significant market share -

SignalChem Biotech provides diverse recombinant Tau proteins for research, helping advance tau-targeted therapies that may modify disease progression in Alzheimer’s and related tauopathies.